Procept BioRobotics announces United Healthcare coverage of Aquablation therapy

PROCEPT BioRobotics Corporation announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation therapy is proven and medically necessary for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia when performed according to the FDA labeled indications, contraindications, warnings and precautions. The updated policy follows Aquablation’s FDA label and is effective June 1, 2023. "We are very excited to announce the updated policy from United Healthcare and believe this will greatly improve accessibility of Aquablation therapy for men suffering from BPH." said Reza Zadno, President and CEO. "With the addition of United Healthcare, we estimate approximately 95% of all men in the United States now have access to Aquablation therapy."